Compile Data Set for Download or QSAR
Report error Found 20 Enz. Inhib. hit(s) with all data for entry = 13134
TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761674(US12377152, Compound 166124)
Affinity DataKd:  30nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761662(US12377152, Compound 166099)
Affinity DataKd:  40nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761677(US12377152, Compound 177032)
Affinity DataKd:  60nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761681(US12377152, Compound 166965)
Affinity DataKd:  220nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761680(US12377152, Compound 163123)
Affinity DataKd:  260nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761674(US12377152, Compound 166124)
Affinity DataKd:  340nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761682(US12377152, Compound 166123)
Affinity DataKd:  410nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761679(US12377152, Compound 180944)
Affinity DataKd:  430nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761682(US12377152, Compound 166123)
Affinity DataKd:  480nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761676(US12377152, Compound 166330)
Affinity DataKd:  590nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761679(US12377152, Compound 180944)
Affinity DataKd:  610nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761678(US12377152, Compound 177033)
Affinity DataKd:  630nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761678(US12377152, Compound 177033)
Affinity DataKd:  650nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761666(US12377152, Compound 165802)
Affinity DataKd:  2.44E+3nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761676(US12377152, Compound 166330)
Affinity DataKd:  2.60E+3nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761662(US12377152, Compound 166099)
Affinity DataKd:  5.63E+3nMAssay Description:(A) Expression and purification of recombinant wild-type human α-synuclein: 0.5 mM IPTG was used to induce production of wild type human α-synuclein ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761680(US12377152, Compound 163123)
Affinity DataKd: >1.00E+4nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM513725(US12377152, Compound 165825)
Affinity DataKd: >1.00E+4nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761681(US12377152, Compound 166965)
Affinity DataKd:  1.00E+4nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent

TargetAlpha-synuclein(Human)
Aprinoia Therapeutics

US Patent
LigandPNGBDBM761666(US12377152, Compound 165802)
Affinity DataKd: >1.00E+4nMAssay Description:PBB5 competition assay: 2 μM of α-synuclein was incubated with 0.26 μM 2-(4-(2-(methylamino)pyridine-5-yl)-1,3-butadiene-1-yl)benzothiazole-6-ol (PBB...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/17/2025
Entry Details
US Patent